HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Potts, L. A. Articles by Garwood, C. L. Search for Related Content PubMed PubMed Citation Articles by Potts, L. A. Articles by Garwood, C. L.

LISA A. POTTS, PHARM.D., is Pharmaceutical Care Specialist, Ambulatory Care, Department of Pharmacy, Cleveland Clinic, Cleveland, OH, and Ambulatory Care Specialty Resident 2005–2006, Department of Pharmacy, Harper University Hospital, Detroit Medical Center (DMC), Detroit, MI. CANDICE L. GARWOOD, PHARM.D., is Ambulatory Care Clinical Pharmacy Specialist, Department of Pharmacy, Harper University Hospital, DMC, and Clinical Assistant Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit.

Address correspondence to Dr. Potts at the Department of Pharmacy, Cleveland Clinic, 9500 Euclid Avenue (W20), Cleveland, OH 44195 (pottsl{at}ccf.org).

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage and administration, and place in therapy of varenicline are reviewed. Summary. Varenicline is the newest therapy approved by the Food and Drug Administration for smoking cessation and the first in its class targeting the neurobiology of nicotine addiction. Varenicline is selective for the 4ß2 acetylcholine-receptor subtype as a partial agonist, thus conferring its effect in limiting the reinforcing aspect of the addictive nicotine molecule. Varenicline is completely absorbed orally and not affected by food. Steady state is reached within four days of administration. Three Phase III clinical trials of varenicline have been published. Two studies compared varenicline with bupropion in patients over age 18 years who smoked more than 10 cigarettes daily. When the data of the two trials were pooled, varenicline use was associated with significant improvements in the four-week carbon-monoxide-confirmed continuous quit rate (44.2% at weeks 9–12 compared with bupropion (29.7%) and placebo (17.7%) (p < 0.0001 for each comparison). The third trial found that continuous quit rates were also significantly higher in patients treated with varenicline versus placebo. Varenicline is generally well tolerated. Varenicline has been administered concurrently with warfarin, digoxin, transdermal nicotine, bupropion, cimetidine, and metformin without any clinically significant drug interactions. Conclusion. Varenicline, a newly approved agent for smoking cessation, offers a new option to patients who cannot tolerate the adverse effects associated with nicotine-replacement therapy and bupropion. It is also an alternative to consider in patients with contraindications to such therapies. Index terms: Absorption; Anticoagulants; Antidepressants; Antidiabetic agents; Autonomic drugs; Bupropion; Cardiac drugs; Cimetidine; Digoxin; Dosage; Drug comparisons; Drug interactions; Food; Gastrointestinal drugs; Mechanism of action; Metformin; Nicotine; Nicotinic agonists; Pharmacokinetics; Smoking; Toxicity; Varenicline; Warfarin

 

This article has been cited by other articles:

				C. L. Garwood and L. A. Potts Emerging pharmacotherapies for smoking cessation Am. J. Health Syst. Pharm., August 15, 2007; 64(16): 1693 - 1698. [Abstract] [Full Text] [PDF]

				K. S. Hudmon The pharmacist's role in tobacco cessation: Overview and introduction to the series Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1434 - 1436. [Full Text] [PDF]